Galapagos receives EU2.5 million IWT grant for antibiotic

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galapagos receives EU2.5 million IWT grant for antibiotic research

MECHELEN, Belgium, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announces that the Flemish Agency for Innovation through Science and Technology (IWT) has awarded a €2.5 million grant to support the development of Galapagos' novel antibiotics in a collaboration project with Prof. Goossens from the University of Antwerp (UA).

GLPG1492 ('1492) is a narrow spectrum antibiotic with a novel mode-of-action against all Staphylococcus aureas strains, including MRSA, the bacteria for which due to resistance, few treatment options are available.  Galapagos plans for '1492 to be dosed in healthy volunteers (Phase 1) in 2015. '1492 has shown excellent antibacterial efficacy, with broad coverage of all known MRSA strains. The novel mode of action for '1492 can be utilized as a platform for addressing gram positive and gram negative bacteria that pose major public health threats, including the ESKAPE pathogens. '1492 is fully proprietary to Galapagos.

Today's grant, awarded via the transformational medical research (TGO) program, was  for the project 'Partnering tiered clinical Phase II anti-MRSA antibiotic with rapid diagnostic test development,' in which Galapagos will collaborate with the Laboratory of Medical Microbiology of UA.  In this project, innovative clinical research will be explored, allowing for more efficient development of narrow spectrum antibiotics targeted at combatting resistance. To further support the pathogenic focus, rapid diagnostic test development will be set up. The UA will perform basic research focusing on further understanding of antibiotic resistance mechanisms.

"We appreciate the support of the IWT for our research," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos. "There is a large unmet medical need for small spectrum antibiotics addressing MRSA and other major public health threats."

Herman Goossens, Head of the Microbiology laboratory of the UA, commented: "By funding this Public Private Partnership between Galapagos and the UA, we should be able to give fresh impetus to the successful development of new drugs against multi-resistant bugs that have already killed so many people worldwide."

About antibiotic resistance and MRSA

Hospital-treated infections of highly resistant bacteria pose a major public health threat. Widespread use of broad spectrum antibiotics addressing a wide variety of pathogens has led to resistance to these treatments. When broad spectrum treatment does not work, the patient is treated in the hospital with small spectrum antibiotics directed specifically toward the pathogen infecting the patient. Due to increasing resistance to broad spectrum antibiotics, the drug market for key hospital-treated infections is expected to increase from $3.3 billion in 2010 to just over $4 billion in 2020 in the USA, the EU and Japan. In particular, there is an urgent need to provide tools to prevent MRSA to become a community acquired infection. Availability of a novel drug that would be able to treat MRSA would be an added value for the public health sector by being able to limit hospitalization time as well the positive impact on the mortality numbers and to avoid further spread.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline comprising three Phase 2 programs, two Phase 1 studies, five pre-clinical, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. In the field of inflammation, AbbVie and Galapagos signed an agreement for the development and commercialization of GLPG0634 . GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012).  GLPG1205, a first-in-class inhibitor of GPR84, is currently being tested in a Phase 2 Proof-of-Concept study in ulcerative colitis patients.  GLPG1690 is a first-in-class compound that targets pulmonary diseases and is currently in a Phase 1 study. AbbVie and Galapagos signed an agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in Phase 1, and corrector GLPG2222 is at the pre-clinical candidate stage. The Galapagos Group, including fee-for-service subsidiary Fidelta, has around 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  Further information at: www.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

HUG#1888743

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 94

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 13

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 156

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 111

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 193

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 69

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 205

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading

Top 5 Most Recently Viewed Articles

First Advantage to Engage Investors at Wolfe FinTech Forum

Updated Category News Views 219

First Advantage to Engage Investors at Wolfe FinTech Forum ATLANTA, March 04, 2025 — First Advantage Corporation (NASDAQ: FA), renowned as a premier provider in employment background screening, identity verification, and other related solutions, is set to showcase its offerings at an upcoming pivotal event. Management of First Advantage will participate in a fireside...

Continue Reading
European Markets Open Strong: EV Collaborations Boost Sentiment

Updated Category News Views 140

European Markets Show Positive Trends European stock markets are beginning the week on a high note, reflecting a cautiously optimistic mood among investors. The overall sentiment is driven by various factors that are currently in play within the financial landscape. The DAX in Germany has risen by 0.4%, while France's CAC 40 has increased by 0.7%. In contrast, the FTSE...

Continue Reading
Southern Company Stock Reaches New Heights, Driven by Growth

Updated Category News Views 81

Southern Company Achieves Record Stock Price Southern Company (NYSE: SO) has recently celebrated a remarkable achievement with its stock price hitting a record high of $91.87. This surge marks an impressive 36.84% increase over the past year, showcasing a growing optimism among investors in the energy sector. The company has been proactive in expanding its operations...

Continue Reading
Exploring GDP Trends: Navigating Economic Uncertainties

Updated Category News Views 337

Understanding Recent GDP Trends The latest economic indicators reveal complexities that question the idea of a resilient economy. Despite these challenges, we remain optimistic for the time being. Let's take a closer look at the current situation: GDP Growth Rate Adjustments The Atlanta Fed’s GDPNow tracking model recently revised its estimated growth rate for the first...

Continue Reading
Live Nation's Ticket Sales Surge Amid Mixed Earnings Report

Updated Category News Views 347

Overview of Live Nation's Recent Performance Live Nation Entertainment, Inc. (NYSE: LYV) witnessed a notable decline in its stock price after the announcement of third-quarter earnings that did not meet market expectations. Despite the drop, the company reported impressive ticket sales and revenue growth. Financial Highlights The entertainment giant reported a substantial...

Continue Reading